The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration
Open accessAbstract
Immune attacks are key issues for cell transplantation. To assess the safety and the immune reactions after iPS cells-derived retinal pigment epithelium (iPS-RPE) transplantation, we transplanted HLA homozygote iPS-RPE cells established at an iPS bank in HLA-matched patients with exudative age-related macular degeneration. In addition, local steroids without immunosuppressive medications were administered. We monitored immune rejections by routine ocular examinations as well as by lymphocytes-graft cells immune reaction (LGIR) tests using graft RPE and the patient’s blood cells. In all five of the cases that underwent iPS-RPE transplantation, the presence of graft cells was indicated by clumps or an area of increased pigmentation at 6 months, which became stable with no further abnormal growth in the graft during the 1-year observation period. Adverse events observed included corneal erosion, epiretinal membrane, retinal edema due to epiretinal membrane, elevated intraocular pressure, endophthalmitis, and mild immune rejection in the eye. In the one case exhibiting positive LGIR tests along with a slight fluid recurrence, we administrated local steroid therapy that subsequently resolved the suspected immune attacks. Although the cell delivery strategy must be further optimized, the present results suggest that it is possible to achieve stable survival and safety of iPS-RPE cell transplantation for a year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This was further confirmed in a clinical trial study with five recruited HLA-matched patients who received HLA-matched RPE cells [97]. In all five cases, survival of transplanted cells was observed one year later, without the need for systemic immune suppression.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061 · cited 8×
“Therefore, the present clinical study was designed to use allografts of iPS-RPE cells from an HLA homozygous donor prepared at the Center for iPS Cell Research and Application (CiRA) iPS bank [21] for wet AMD patients with the same HLA haplotype identity.”
BackgroundMethodInfluentialSelf-citationPrevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509 · cited 4×
“The marker and function for the iPS cells-derived RPE cells were similar to that observed with our previous RPE cells [20].”
BackgroundMethodResultInfluentialSelf-citationImmunogenicity of induced pluripotent stem cells
Zhao, T., Zhang, Z.-N., Rong, Z., & Xu, Y. (2011) · Nature · doi:10.1038/nature10135 · Cited by 1,444 · cited 1×
“Moreover, we have as of yet no definitive answer as to how the immune rejection in the eye occurred in only one case, even though several events such as iPS-associated immune attacks [32], minor antigens, natural killer cell attacks (e.”
BackgroundEmbryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409 · cited 1×
“However, it was also found that some of these patients had adverse events due to systemic immunosuppressive medications [28], which can be a physical burden in elderly patients.”
BackgroundSchwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 1×
“However, anti-VEGF treatments often require continual injections for years and thus, it can be difficult to retain visual acuity in real-world clinics [8].”
BackgroundThe Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807 · cited 2×
“Moreover, the eye is also known to be a unique organ with a unique environment that has both anti-inflammatory and immunosuppressive mechanisms [16,17].”
Background
Cited by
Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges
Yamanaka, S. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.09.014 · Cited by 1,213
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
Kirkeby, A., Main, H., & Carpenter, M. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2024.12.005 · Cited by 196
Yoshida, S., Kato, T., Sato, Y., Umekage, M., Ichisaka, T., Tsukahara, M., Takasu, N., & Yamanaka, S. (2022) · Med · doi:10.1016/j.medj.2022.10.003 · Cited by 160
Hirami, Y., Mandai, M., Sugita, S., Maeda, A., Maeda, T., Yamamoto, M., Uyama, H., Yokota, S., Fujihara, M., Igeta, M., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.11.004 · Cited by 138
Self-citationJarrige, M., Frank, E., Herardot, E., Martineau, S., Darle, A., Benabidès, M., Domingues, S., Chose, O., Habeler, W., Lorant, J., et al. (2021) · Cells · doi:10.3390/cells10020240 · Cited by 116
“A clinical trial in Japan used one HLA-matched hiPSC-RPE cell line to treat five wet-AMD patients [125].”
Method
Metadata
- Authors
- Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hono, A., Fujino, S., Koide, N., Sakai, N., Shibata, Y., Terada, M., Nishida, M., Dohi, H., Nomura, M., Amano, N., Sakaguchi, H., Hara, C., Maruyama, K., Daimon, T., Igeta, M., Oda, T., Shirono, U., Tozaki, M., Totani, K., Sugiyama, S., Nishida, K., Kurimoto, Y., & Takahashi, M.
- Affiliations
- RIKEN Center for Biosystems Dynamics Research (JP)
- Kobe City Medical Center General Hospital (JP)
- Toho University (JP)
- Kyoto University (JP)
- The University of Osaka (JP)
- Hyogo Medical University (JP)
- Tomey Corporation (Japan) (JP)
- Corresponding author
- Takahashi, Masayo
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-07-13
- Volume
- 9
- Issue
- 7
- Pages
- 2217
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7408794
- OpenAlex
- W3041366976
- Cited by
- 190
- References
- 33
- Citations by year
- 2026: 27 · 2025: 28 · 2024: 34 · 2023: 24 · 2022: 36 · 2021: 36 · 2020: 5
- FWCI
- 8.18
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- AMED (JP18bm0204002, JP17bk0104002)
- KAKENHI (25293357, 18H02959, 16K21633)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Keywords
- induced pluripotent stem cells, retinal pigment epithelium, cell transplantation, age-related macular degeneration, HLA matching, immune rejection, local steroid therapy, graft survival, transplant safety, epiretinal membrane, endophthalmitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration. https://app.cochat.ai/papers/10.3390/jcm9072217
- The paper
- Sugita, S., Mandai, M., Hirami, Y., Takagi, S., Maeda, T., Fujihara, M., Matsuzaki, M., Yamamoto, M., Iseki, K., Hayashi, N., Hono, A., Fujino, S., Koide, N., Sakai, N., Shibata, Y., Terada, M., Nishida, M., Dohi, H., Nomura, M., . . . Takahashi, M. (2020). HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9072217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.